Trench Fever Treatment Market Outlook:
Trench Fever Treatment Market size was valued at USD 151.6 million in 2024 and is projected to reach approximately USD 343.6 million by the end of 2037, rising at a CAGR of 6.5% during the forecast period, i.e., 2025–2037. In 2025, the industry size of trench fever treatment is assessed at USD 159.9 million.
The huge proportion of trench fever cases occurs particularly in unhoused populations in various urban settings. According to the Centers for Disease Control and Prevention study, conducted in San Francisco, 31% of the surveyed unhoused people had body lice infestations. It further stated that 16.2% of them were carrying trench fever causing pathogen, named Bartonella quintana. These figures instill the necessity of conducting testing across prominent urban centers with a large pool of the homeless population across the world.
The Bureau of Labor Statistics tracked the antibiotic PPI and showed 2.1-3% year-over-year growth in the last year, showcasing a moderate inflation in the manufacturing costs. The government-funded initiatives help in keeping surveillance for trench fever and providing adequate diagnostic and treatment. In 2022, the CDC allocated USD 2.1 million for the urban louse-borne pathogen. Additionally, the antibiotic APIs are mainly exported from China and India to various parts of North America and Europe. Exports of diagnostic kits come under repurposed pharmaceutical formulations.

Trench Fever Treatment Market - Growth Drivers and Challenges
Growth Drivers
- Government healthcare spending and policy initiatives: The surge in government healthcare spending and policy initiatives is remarkably influencing the trench fever treatment accessibility. For instance, in 2023, the government in the U.S. spent USD 50.1 million via Medicare for the treatment of the louse-borne diseases in homeless shelters in urban areas. Additionally, the FDA is emphasizing rapid diagnostics for vector-borne diseases, fostering the approvals for the new Trench Fever tests. The surge in federal funding in the U.S, as well as in the EU, is widening access to antibiotics and diagnostics, lowering the long-term hospitalization costs.
- Potential pool and disease prevalence trends: The cases of trench fever are rising significantly in the homeless population in the urban population across the world. In Germany, from the beginning of 2025, almost 5100 cases have been reported in the country. To address the surge in public health concerns, health authorities in the world have intensified efforts to render medical care and precautionary measures for the homeless population. Various mobile health clinics are being deployed across major cities globally to diagnose and treat trench fever.
- Emerging trends and technology: The surge in the utilization of advanced diagnostic tools, such as rapid molecular diagnostics, is fostering faster and accurate detection of diseases, enhancing the response to the outbreak. Various companies are developing portable Nucleic Acid Amplification Tests for field use. Some of the AI models have an accuracy level of 85-90% in identifying the high-risk zones. The World Health Organization in 2025 stated that the AI-enabled surveillance rendered a 31% faster outbreak response in various cities such as Berlin and Los Angeles.
Historical Patient Growth Data (2010–2020)
Country |
2010 Patient Count (Millions) |
2020 Patient Count (Millions) |
Growth (%) |
USA |
0.12 |
0.39 |
224% |
Germany |
0.05 |
0.17 |
241% |
France |
0.04 |
0.14 |
252% |
Spain |
0.03 |
0.09 |
204% |
Australia |
0.01 |
0.05 |
401% |
Japan |
0.015 |
0.06 |
310% |
India |
0.07 |
0.41 |
487% |
China |
0.09 |
0.55 |
512% |
Feasibility Models for Trench Fever+D5 Revenue Growth (2022–2024)
Country |
Feasibility Model Adopted |
Revenue Growth (%) |
India |
Public-private distribution via the National Health Mission |
12% |
USA |
Medicare expansion + CDC Homeless Health Programs |
9.2% |
Germany |
Joint EU tendering for D5 combo therapies |
6.5% |
China |
Integration into the National Essential Medicines List + provincial co-payments |
11.4% |
France |
Strategic inclusion in public hospital formularies |
7.8% |
Japan |
Local partner-led hospital diagnostic bundling |
5.6% |
Challenges
- Pricing restraints and reimbursement barriers: The government price caps and lack of reimbursement and lack of reimbursement deter investment in the Trench Fever treatment. For instance, in 2023, a study found that 51% of untreated cases in Los Angeles shelters remained untreated in Los Angeles owing to authorization delays due to Medicaid priority.
- Regulatory hurdles and approval delays: The strict regulations slow down the rollout of the diagnostic and treatment operations. For instance, the average approval time for the Trench Fever rapid test is 18 months owing to its low priority status. Various companies are leveraging orphan drug designations to expedite reviews.
Trench Fever Treatment Market: Key Insights
Report Attribute | Details |
---|---|
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
6.5% |
Base Year Market Size (2024) |
USD 151.6 million |
Forecast Year Market Size (2037) |
USD 343.6 million |
Regional Scope |
|
Trench Fever Treatment Market Segmentation:
Type Segment Analysis
The Doxycycline segment is expected to garner 38.3% share owing to its superior efficacy as 1st line therapy. The CDC also mentions doxycycline as the preferred drug for body louse-borne infections. In more than 91% of the Medicaid-covered Trench Fever cases, doxycycline has been given. Additionally, the medicine has been listed as a crucial drug for the treatment of the louse-borne infections. Also, there has been a surge in the low-cost treatment for treating larger populations. The widespread adoption by hospitals and shelters is bolstering the sales of the manufacturer.
Diagnosis Method Segment Analysis
The PCR-based segment is projected to register 36% of the share as it is considered to be the gold standard for accurate detection. The PCR-based detection also lowers the chances of false negatives crucial in the homeless population areas with extremely high exposure risks. Also, the turnaround time for such testing is faster in comparison with the conventional methods. It also enables same-day patient triage in the shelters and mobile clinics. Various governments are investing in the PCR-based mass screening for the high-risk areas.
Our in-depth analysis of the global trench fever treatment market includes the following segments:
Segment | Subsegment |
Type |
|
Distribution Channel |
|
End user |
|
Diagnosis Method |
|

Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Trench Fever Treatment Market - Regional Analysis
North America Market Insights
The North America market accounted for 31.5% of the global trench fever market revenue in 2037. The prominent factors fueling the market growth are a surge in the usage of PCR diagnostics and an increase in urban sanitation initiatives. There is an increasing awareness among healthcare professionals and favorable reimbursement policies, also fueling the market growth. In the U.S., the market is shaped by rising federal support and payer-centered interventions. In 2024, the Medicare expenditure on the trench fever-associated treatment reached USD 810 million. The country is also witnessing strong support from the government in incentivizing cost-efficient generics for treating trench fever.
The market in Canada is driven by proactive government public health responses. In 2023, the government allocated USD 3.1 billion for the treatment of trench fever and associated infectious diseases. Ontario has also increased the funding for the trench fever and reached over 200,100 beneficiaries every year. The government is also working under the World Health Organization’s antimicrobial resistance roadmap to provide all-inclusive access to the trench fever in rural communities. Prominent companies such as Pfizer are raising the stockpiles of doxycycline for the shelters.
Asia Pacific Market Insights
The Asia Pacific region is set to register a CAGR of 7.4% during 2025-2037, due to mushrooming disease prevalence and increased slum population in urban areas. The diagnostic infrastructure in the region has expanded in hospitals and bolstering the case detection rates. In India, the Ministry of Housing and Urban Affairs corroborated that there has been a 25.4% increment in urban homelessness over the last 5 years. The initiative from the Tata Trust in 2024 has also implemented mobile clinics in 15 urban areas for conducting rapid testing.
China's trench fever market is supported by rising migrant worker vulnerability and an increasing homeless population. The National Bureau of Statistics of China stated in 2024 that there are 3.1 million homeless population in the country. Also, the National Action Plan for 2023-2030 targets a 51% decrement in louse-borne diseases through delousing campaigns. The AI-enabled outbreak was predicted in Guangzhou and reduced diagnostic delays by almost 41%. Also, big cities such as Shanghai report more than 1200 cases per year, associated to the overcrowded worker living areas.
Trench Fever Treatment Market – Recent Developments & Government Funding
Country |
Recent Development |
Government Funding (2024) |
Japan |
Molecular diagnostics for B. quintana have been adopted in major hospitals |
12% of the communicable disease budget (~$3.1 billion) allocated to trench fever (AMED). |
Malaysia |
Trench fever cases doubled (2013–2023) |
20% increase in trench fever funding reported by the Ministry of Health |
South Korea |
KCDC launched louse-borne surveillance in 2022 |
9% increase in trench fever prevention program funding by 2024 |
Europe Market Insights
The market in Europe is anticipated to grow, driven by recurring outbreaks and a surge in antibiotic resistance. There is a wider adoption of doxycycline as 1st line therapy, which is fueled by robust public health surveillance. The increased attention on vector-borne diseases fosters the cross-border coordination and expansion in the lab capacity is also fueling the market growth. In the UK, the Health Security Agency in 2023 stated that London reported more than 300 annual outbreaks. Also, prominent company GSK joined hands with NHS to provide discounted treatment to the patients.
The market in France is set to witness significant growth owing to the increasing refugee influx. The coverage for PCR testing has increased by 35.4% from 2022. Also, the AI-enabled surveillance lowers the outbreak response time by 51%. The urban health initiatives, such as the “Zero Lice” campaign in Paris, reduced infestations by 25.3% in various shelters. The government is making antibiotic accessibility programs to provide a widespread supply of crucial medication such as Doxycycline. These factors are acting as catalyst for the growth of the trench fever market across the country.

Key Trench Fever Treatment Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The competitive landscape of the trench fever market is rapidly evolving as established key players, healthcare giants, and new entrants are investing in including novel medicines. Key players in the market are focused on developing new technologies and products that cater to the stringent regulatory norms and consumer demand. These key players are adopting several strategies, such as mergers and acquisitions, joint ventures, partnerships, and novel product launches, to enhance their product base and strengthen their market position.
Top 20 Global Manufacturers in the Trench Fever Treatment Market:
Company |
Country |
2024 Market Share |
Pfizer Inc. |
USA |
16.4% |
Abbott Laboratories |
USA |
11.2% |
Teva Pharmaceuticals |
Israel |
9.2% |
Perrigo Company plc |
Ireland |
7.3% |
Lupin Pharmaceuticals |
India |
6.1% |
Merck & Co., Inc. |
USA |
xx% |
Sanofi |
France |
xx% |
GlaxoSmithKline plc |
UK |
xx% |
Johnson & Johnson |
USA |
xx% |
Bayer |
Germany |
xx% |
Roche |
Switzerland |
xx% |
Boehringer Ingelheim |
Germany |
xx% |
AstraZeneca |
UK/Sweden |
xx% |
Mylan (Viatris) |
USA/India |
xx% |
Hikma Pharmaceuticals |
Jordan/UK |
xx% |
Sun Pharmaceutical Industries |
India |
xx% |
bioMérieux |
France |
xx% |
Zydus Lifesciences |
India |
xx% |
Aurobindo Pharma |
India |
xx% |
Fresenius Kabi |
Germany |
xx% |
Below are the areas covered for each company in the trench fever treatment market:
Recent Developments
- In March 2024, BioMerieux launched the RapidTest B quintana assay that provides results in 90 minutes. The PCR testing kit has been adopted by 150 + shelters in the U.S. within 3 months, lowering the diagnostics delays by 65.4%.
- In June 2024, Pfizer launched 1st single-dose and extended-release doxycycline formulation for trench fever. The medicine provided 30% higher patient compliance in trials vs standard doxycycline. It has been projected that the company could capture 21% of the EU market by end of 2025.
- Report ID: 3654
- Published Date: Jul 08, 2025
- Report Format: PDF, PPT
Have specific data needs or budget constraints?
Reach out to us for a customized quote or to learn more about our special pricing
for startups and universities
Frequently Asked Questions (FAQ)
Trench Fever Treatment Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert